



Drug Transporters in ADME: From the Bench to the Bedside

George Mason University – Mason Square | Arlington, VA

Monday, April 8, 2024

7:00 AM – 8:00 AM	Continental Breakfast
8:00 AM – 10:00 AM	Morning Plenary: ITC Update and Hot Topic – Molecular Basis for Drug Transport
8:00 AM – 8:05 AM	Introduction and Welcome Bridget Morse, Ph.D., Eli Lilly
8:05 AM – 9:00 AM	Membrane Transporters in Drug Development and as Key Determinants of Precision Medicine: An Update from the International Transporter Consortium Alex Galetin, University of Manchester
9:00 AM – 9:30 AM	Molecular Basis of Polyspecific Drug Recognition by OCT1 and OCT2 Seok Yong Lee, Duke University
9:30 AM – 10:00 AM	Molecular Basis for Selective Uptake and Elimination of Organic Anions in the Kidney by OAT1 Representative from University of Oxford
10:00 AM – 10:30 AM	Coffee Break
10:30 AM – 12:00 PM	Session Two: Transporters Models and Methods Wei Yue
10:30 AM – 11:00 AM	In Vitro Hepatocyte-Culture System for Biliary Excretion Analysis by Permeation Assay Ikumi Tamai, Kanazawa University
11:00 AM – 11:30 AM	Demystifying Xenobiotic Transport Mechanisms at the Blood-CSF Barrier Using Live Tissue Imaging Joanne Wang, University of Washington
11:30 AM – 12:00 PM	Effect of Sex and Cross-Sex Hormone Treatment on Renal Monocarboxylate-Transporter Expression in Rats Melanie Felmee, University of the Pacific

12:00 PM – 12:30 PM	Partner Presentation
12:30 PM – 1:30 PM	Lunch and Exhibits
1:30 PM – 3:00 PM	Session Three: Emerging Transporters & Mechanisms Paresh Chothe
1:30 PM – 2:00 PM	Nucleoside transporters Rajgopal Govindarajan, The Ohio State University
2:00 PM – 2:30 PM	Organic Cation Transporter 2 Contributes to SSRI Antidepressant Efficacy by Controlling Tryptophan Availability in the Brain Sophie Gautron, Sorbonne University
2:30 PM – 3:00 PM	Consequences of Altered Kinase Activity and Solute Carrier Function Jason Sprowl, University of Buffalo
3:00 PM – 3:30 PM	Coffee Break
3:30 PM – 5:00 PM	Session Four: Rapid Fires and Partner Presentation
3:30 PM – 4:00 PM	Partner Presentation
4:00 PM – 5:00 PM	Rapid Fires
5:00 PM – 7:00 PM	Evening Reception and Exhibits

Tuesday, April 9, 2024

7:00 AM – 8:00 AM	Continental Breakfast
8:00 AM – 10:00 AM	Session Five: Rapid Fires and Partner Presentations
8:00 AM – 8:30 AM	Partner Presentation
8:30 AM – 9:30 AM	Rapid Fires
9:30 AM – 10:00 AM	Partner Presentation
10:00 AM – 10:30 AM	Coffee Break
10:30 AM – 12:00 PM	Session Six: Transporters in Clinical Pharmacology Xinning Yang
10:30 AM – 11:00 AM	Ticagrelor Increases Exposure to the Breast Cancer Resistance Protein Substrate Rosuvastatin Mikko Niemi, University of Helsinki

11:00 AM – 12:00 PM	Case Studies
12:00 PM – 1:00 PM	Lunch and Exhibits
1:00 PM – 5:00 PM	Session Seven: Prediction of Transporter-Mediated Clearance, DDIs and Disease Effects Matthew Harwood Bridget Morse, Ph.D., Eli Lilly
1:00 PM – 1:30 PM	Transporter-Mediated Clearance and Drug-Drug Interactions – Identifying Mechanisms and Predicting Effect Size Manthena Varma, Pfizer, Inc.
1:30 PM – 2:00 PM	Plasma Protein-Mediated Uptake and Contradictions to the Free Drug Hypothesis: A Critical Review John Cory Kalvass, AbbVie
2:00 PM – 2:30 PM	Toward Improved Predictions of Pharmacokinetics of Transported Drugs in Hepatic Impairment: Insights from the Extended Clearance Model Flavia Storelli, University of Washington
2:30 PM – 3:00 PM	Coffee Break
3:00 PM – 3:30 PM	Clinical Implications of Altered Drug Transporter Abundance/Function and PBPK Modeling in Specific Populations: An ITC Perspective Xiaoyan Chu, Merck & Co., Inc.
3:30 PM – 4:00 PM	Renal Transporter Alterations in Patients with Chronic Liver Diseases: Nonalcoholic Steatohepatitis, Alcohol-Associated, Viral Hepatitis, and Alcohol-Viral Combination Nathan Cherrington, University of Arizona
4:00 PM – 4:30 PM	Predicting Statin-Roxadustat Drug-Drug Interaction in Patients with Severe Chronic Kidney Disease to Support Prescribing Information Using Physiologically Based Pharmacokinetic Modelling Jin Dong, AstraZeneca
4:30 PM – 5:00 PM	Prediction of Transporter-Mediated Clearance, DDIs and Disease Effects Panel Discussion
5:00 PM – 7:00 PM	Evening Reception and Exhibits

Wednesday, April 10, 2024

7:00 AM – 8:00 AM	Continental Breakfast
8:00 AM – 10:00 AM	Session Eight: Regulatory Considerations Xiaoyan Chu
8:00 AM – 8:30 AM	Harmonization on DDI Guidances for Transporters-Mediated DDIs: Current Status and Future Xinning Yang, Ph.D., FDA
8:30 AM – 9:00 AM	Regulatory Considerations for Transporter Mediated Drug-Drug Interactions (EMA Perspective) Carolien Versantvoort, European Medicines Agency
9:00 AM – 9:30 AM	Trends in FDA Transporter-Based Post-Marketing Requirements and Commitments Over the Last Decade Islam Younis, Merck & Co., Inc.
9:30 AM – 10:15 AM	Panel Discussion
10:15 AM – 10:45 AM	Coffee Break
10:45 AM – 12:00 PM	Session Nine: Closing Keynote Wei Yue
10:45 AM – 11:45 AM	The Mitochondrial Transporter ABCB10 Regulates Redox and Cell-to-Cell Communication in Metabolic Diseases Marc Liesa, Spanish National Research Council
11:45 AM – 12:00 PM	Closing Remarks Bridget Morse, Ph.D., Eli Lilly